Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective randomized controlled study to compare efficacy of ibandronate and denosumab as sequential therapy following 12-month romosozumab treatment in with severe postmenopausal osteoporosis

Next Previous
Search
Trial Profile

A prospective randomized controlled study to compare efficacy of ibandronate and denosumab as sequential therapy following 12-month romosozumab treatment in with severe postmenopausal osteoporosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denosumab (Primary) ; Ibandronic acid (Primary) ; Romosozumab (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Acronyms VICTOR

    • Most Recent Events

    • 01 Sep 2022 Primary endpoint has been met (The percentage changes in BMD at the lumbar spine, total hip, and femoral neck from 12 months (completion of romosozumab) to 18 and 24 months of total treatment (6 and 12 months, respectively, after the conversion to sequential therapy)) , according to Results published in the Bone
    • 01 Sep 2022 Results published in the Bone
    • 05 Aug 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top